Tobias Herold1, Nicola Gökbuget2. 1. Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Marchioninistr. 15, 81377, Munich, Germany. tobias.herold@med.uni-muenchen.de. 2. Department of Medicine II, Goethe University Hospital, Frankfurt, Germany.
Abstract
PURPOSE OF REVIEW: This study aims to provide an overview of the classification, incidence, genomic alterations, and clinical implications of Philadelphia-like Acute Lymphoblastic Leukemia (Ph-like ALL) in adults. RECENT FINDINGS: Ph-like ALL is a high-risk subtype of B cell precursor ALL with characteristic genomic alterations in children and adults. A standard approach for diagnosis is missing and currently mainly based on gene expression analysis. The incidence is age depended and highest in adolescents and younger adults (age 16-39) where 19-28% of patients belong to this subtype. Ph-like ALL is associated with persistence of minimal residual disease (MRD) and inferior prognosis. Some genomic alterations respond to specific treatment approaches and provide hope for tailored therapies. Ph-like ALL in adults is an aggressive and high-risk subtype of B cell precursor ALL. Without consensus definition, diagnosis is difficult and current publications highlight the importance of stringent MRD monitoring to guide risk-adapted treatment strategies.
PURPOSE OF REVIEW: This study aims to provide an overview of the classification, incidence, genomic alterations, and clinical implications of Philadelphia-like Acute Lymphoblastic Leukemia (Ph-like ALL) in adults. RECENT FINDINGS: Ph-like ALL is a high-risk subtype of B cell precursor ALL with characteristic genomic alterations in children and adults. A standard approach for diagnosis is missing and currently mainly based on gene expression analysis. The incidence is age depended and highest in adolescents and younger adults (age 16-39) where 19-28% of patients belong to this subtype. Ph-like ALL is associated with persistence of minimal residual disease (MRD) and inferior prognosis. Some genomic alterations respond to specific treatment approaches and provide hope for tailored therapies. Ph-like ALL in adults is an aggressive and high-risk subtype of B cell precursor ALL. Without consensus definition, diagnosis is difficult and current publications highlight the importance of stringent MRD monitoring to guide risk-adapted treatment strategies.
Authors: Pier Paolo Piccaluga; Mario Arpinati; Anna Candoni; Claudio Laterza; Stefania Paolini; Anna Gazzola; Elena Sabattini; Giuseppe Visani; Stefano A Pileri Journal: Leuk Lymphoma Date: 2010-11-15
Authors: H Lilljebjörn; H Ågerstam; C Orsmark-Pietras; M Rissler; H Ehrencrona; L Nilsson; J Richter; T Fioretos Journal: Leukemia Date: 2013-11-04 Impact factor: 11.528
Authors: Francois P Duhoux; Nathalie Auger; Sigrid De Wilde; Sebastian Wittnebel; Geneviève Ameye; Khadija Bahloula; Catherine Van den Berg; Jeanne-Marie Libouton; Pascale Saussoy; Francis H Grand; Jean-Baptiste Demoulin; Hélène A Poirel Journal: Leuk Res Date: 2011-03-09 Impact factor: 3.156
Authors: Jennifer Richmond; Alissa Robbins; Kathryn Evans; Dominik Beck; Raushan T Kurmasheva; Catherine A Billups; Hernan Carol; Sue Heatley; Rosemary Sutton; Glenn M Marshall; Deborah White; John Pimanda; Peter J Houghton; Malcolm A Smith; Richard B Lock Journal: Cancer Res Date: 2016-06-14 Impact factor: 12.701
Authors: Richard C Harvey; Charles G Mullighan; I-Ming Chen; Walker Wharton; Fady M Mikhail; Andrew J Carroll; Huining Kang; Wei Liu; Kevin K Dobbin; Malcolm A Smith; William L Carroll; Meenakshi Devidas; W Paul Bowman; Bruce M Camitta; Gregory H Reaman; Stephen P Hunger; James R Downing; Cheryl L Willman Journal: Blood Date: 2010-02-04 Impact factor: 22.113
Authors: Michelle L Churchman; Jonathan Low; Chunxu Qu; Elisabeth M Paietta; Lawryn H Kasper; Yunchao Chang; Debbie Payne-Turner; Mark J Althoff; Guangchun Song; Shann-Ching Chen; Jing Ma; Michael Rusch; Dan McGoldrick; Michael Edmonson; Pankaj Gupta; Yong-Dong Wang; William Caufield; Burgess Freeman; Lie Li; John C Panetta; Sharyn Baker; Yung-Li Yang; Kathryn G Roberts; Kelly McCastlain; Ilaria Iacobucci; Jennifer L Peters; Victoria E Centonze; Faiyaz Notta; Stephanie M Dobson; Sasan Zandi; John E Dick; Laura Janke; Junmin Peng; Kiran Kodali; Vishwajeeth Pagala; Jaeki Min; Anand Mayasundari; Richard T Williams; Cheryl L Willman; Jacob Rowe; Selina Luger; Ross A Dickins; R Kiplin Guy; Taosheng Chen; Charles G Mullighan Journal: Cancer Cell Date: 2015-08-27 Impact factor: 31.743
Authors: Shannon L Maude; Sarah K Tasian; Tiffaney Vincent; Junior W Hall; Cecilia Sheen; Kathryn G Roberts; Alix E Seif; David M Barrett; I-Ming Chen; J Racquel Collins; Charles G Mullighan; Stephen P Hunger; Richard C Harvey; Cheryl L Willman; Jordan S Fridman; Mignon L Loh; Stephan A Grupp; David T Teachey Journal: Blood Date: 2012-09-06 Impact factor: 22.113
Authors: Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone Journal: Blood Date: 2013-11-25 Impact factor: 22.113